These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22272343)

  • 1. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.
    Shin YJ; Kim JH
    PLoS One; 2012; 7(1):e30393. PubMed ID: 22272343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
    Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
    Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
    Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
    Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3.
    Jia J; Li F; Tang XS; Xu S; Gao Y; Shi Q; Guo W; Wang X; He D; Guo P
    Oncotarget; 2016 Jun; 7(25):37868-37881. PubMed ID: 27191265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer.
    Xu C; Hou Z; Zhan P; Zhao W; Chang C; Zou J; Hu H; Zhang Y; Yao X; Yu L; Yan J
    Med Oncol; 2013 Dec; 30(4):713. PubMed ID: 24132606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
    Karanikolas BD; Figueiredo ML; Wu L
    Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
    Karanikolas BD; Figueiredo ML; Wu L
    Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
    Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
    Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells.
    Bryant RJ; Winder SJ; Cross SS; Hamdy FC; Cunliffe VT
    Prostate; 2008 Feb; 68(3):255-63. PubMed ID: 18095286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
    Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
    Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
    Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
    Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
    Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression.
    Zhu J; Yang DR; Sun Y; Qiu X; Chang HC; Li G; Shan Y; Chang C
    Mol Cancer Ther; 2015 Jun; 14(6):1445-53. PubMed ID: 25833838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
    Figueira RC; Gomes LR; Neto JS; Silva FC; Silva ID; Sogayar MC
    BMC Cancer; 2009 Jan; 9():20. PubMed ID: 19144199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.